Alkem Laboratories Ltd.

As of June 30, 2026, Alkem Laboratories Ltd. carries a market capitalization of 665.98B, placing it among publicly traded companies globally. Its enterprise value stands at 665.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alkem Laboratories Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Alkem Laboratories Ltd. has 119.57M shares outstanding.

As of June 30, 2026, Alkem Laboratories Ltd. trades at a trailing price-to-earnings ratio of 30.87.

As of June 30, 2026, Alkem Laboratories Ltd. trades at an EV/EBITDA multiple of 23.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.18 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 665.98B versus a market cap of 665.98B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.53M in revenue per employee across its workforce of 23,109.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Alkem Laboratories Ltd. recorded 6.66B in income tax expense. That works out to an effective tax rate of 23.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.72B, leaving 21.58B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Alkem Laboratories Ltd.'s stock has declined approximately 9.63% over the past 52 weeks. The 50-day moving average sits at 5,269.17, while the 200-day moving average is 5,459.80.

Over the twelve months ended June 30, 2026, Alkem Laboratories Ltd. generated 150.81B in revenue and converted that into 21.58B in net income, yielding earnings per share of 184.34. EBITDA reached 28.44B, while operating income came in at 26.38B.

Over the twelve months ended June 30, 2026, Alkem Laboratories Ltd. posted a gross margin of 66.03, reflecting its pricing power and cost economics. The operating margin of 17.49 and net profit margin of 14.31 provide insight into operational efficiency.